Although both genes encode proteins that participate in the HR pathway, the reason why germline BRCA1 mutations seem to confer a higher risk of developing ovarian cancer than germline BRCA2 mutations is probably related to their earlier and more substantial role in DNA damage response and cell-cycle regulation. The gene discussed is BRCA1; the disease is ovarian carcinoma.